Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Business Strategies Pricing Strategies Market Intelligence

Novo Finance Group's New CEO Will Put More Cash To Work Internationally

Executive Summary

Healthcare banking veteran, Kasim Kutay, who last month took over as CEO of Novo A/S – a $57bn holding and investment group with a focus on life sciences but a broad setup for all levels of capital provision from seed investment, venture capital to larger, long term investments – talks to Scrip about the challenges for commercialization strategies on the back of the recent wave of R&D productivity and the ongoing uptick for innovation in drug development.

Table

View full table

Topics

Related Companies

Tags:
Business Strategies Pricing Strategies Market Intelligence
Latest Headlines

Pfizer Matches Beqvez Price To Hemgenix In Hemophilia B, Plans Warranty Program

Analysis: Novo And Lilly Make Their Money Work

AstraZeneca’s Hot Streak Whets Investor Appetite For What’s Next

Sweden's InDex To Stay Afloat Thanks To Mystery Merger Partner

See All
UsernamePublicRestriction

Register

SC097445

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By